Moderna Inc
$ 40.51
-3.54%
11 Feb - close price
- Market Cap 16,408,859,000 USD
- Current Price $ 40.51
- High / Low $ 40.80 / 36.66
- Stock P/E N/A
- Book Value 23.86
- EPS -8.07
- Next Earning Report 2026-02-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.29 %
- 52 Week High 55.20
- 52 Week Low 22.28
About
Moderna, Inc. is a leading biotechnology firm based in Cambridge, Massachusetts, widely recognized for its groundbreaking work in vaccine development utilizing proprietary messenger RNA (mRNA) technology. Following its pivotal contribution to the rapid development of one of the first effective COVID-19 vaccines, the company is expanding its research focus to include a variety of conditions such as cancer, rare diseases, cardiovascular disorders, and autoimmune diseases. With a promising pipeline and an unwavering commitment to scientific innovation, Moderna aims to redefine healthcare by effectively addressing significant unmet medical needs and improving patient outcomes globally.
Analyst Target Price
$38.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-01 | 2025-04-30 | 2025-02-20 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.51 | -2.13 | -2.52 | -2.91 | 0.03 | -3.33 | -3.07 | 0.55 | -9.53 | -3.62 | 0.19 | 3.61 |
| Estimated EPS | -2.05 | -2.98 | -3.03 | -2.7599 | -1.9 | -3.38 | -3.58 | -0.97 | -1.93 | -4.04 | -1.77 | 4.68 |
| Surprise | 1.54 | 0.85 | 0.51 | -0.1501 | 1.93 | 0.05 | 0.51 | 1.52 | -7.6 | 0.42 | 1.96 | -1.07 |
| Surprise Percentage | 75.122% | 28.5235% | 16.8317% | -5.4386% | 101.5789% | 1.4793% | 14.2458% | 156.701% | -393.7824% | 10.396% | 110.7345% | -22.8632% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-13 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -2.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MRNA
2026-02-11 21:27:41
BioNTech SE, known for its pivotal role in pandemic vaccines, is now focusing on applying its mRNA technology to cancer and infectious disease treatments. While its stock (BNTX) has seen a significant drop from its pandemic peak, the article suggests it's a potential high-risk, high-reward investment for long-term believers in biotech's future, rather than a quick win for short-term traders. The company is positioned as a deep science player in contrast to its flashier competitor, Moderna, making it a "must-watch" for those betting on future medical advancements.
2026-02-11 17:49:44
Mexico has signed a five-year agreement with Moderna to bolster its mRNA vaccine supply for respiratory diseases. The deal involves Moderna supplying its respiratory vaccine portfolio and transferring its Covid-19 vaccine technology to Mexican pharma company Liomont, enabling local production. This initiative, part of Mexico's "Plan Mexico" for economic growth and local production capacity, contrasts with recent US regulatory resistance to Moderna's mRNA flu vaccine candidate.
2026-02-11 14:56:58
This article lists several stocks to watch on Wednesday, including Netflix, QXO, Moderna, and SLB. It specifically highlights Unity Software's (U.US) fourth-quarter earnings, noting that its revenue increased 35% year-over-year to $609 million, surpassing the consensus estimate. The company, however, reported a quarterly loss of 66 cents per share.
2026-02-11 14:15:12
The article "Money Matters" reports on two distinct news items. Firstly, the FDA rejected Moderna's application for a flu vaccine, indicating a setback for the pharmaceutical company. Secondly, Hershey's is embracing the Olympic spirit by offering chocolate Olympic medals, suggesting a new marketing initiative or product offering.
2026-02-11 10:27:37
Tuya Inc. (HK:2391) is holding a board meeting on March 2, 2026, to review its unaudited Q4 2025 and audited full-year 2025 results, and to consider a cash dividend. An earnings call is scheduled for March 3, 2026, which may signal increased transparency and potential returns for shareholders. Analysts currently rate the stock as a Buy with a HK$28.00 price target.
2026-02-11 02:29:38
Septerna, Inc. is set to present Phase 1 clinical trial data for its drug candidate SEP-631 at the American Academy of Allergy Asthma & Immunology Annual Meeting. The presentation will detail the first-in-human study of SEP-631, an oral small molecule targeting the MRGPRX2 receptor for chronic spontaneous urticaria and other mast cell-driven diseases. Analysts have issued "strong buy" ratings for Septerna with price targets indicating significant upside, reflecting optimism about the company's clinical advancements and proprietary drug discovery platform.
